Acceptys and OncoMab to integrate antibody drug development
Two privately held biopharmaceutical companies focused on the development of human antibody therapies - Acceptys of New York, US, and OncoMab of Wurzburg, Germany - are to combine their human antibody therapeutic pipelines and research operations.
Two privately held biopharmaceutical companies focused on the development of human antibody therapies - Acceptys of New York, US, and OncoMab of Wurzburg, Germany - are to combine their human antibody therapeutic pipelines and research operations.
Under a new deal, Acceptys has the right to evaluate, acquire and develop all eight lead antibody therapeutic candidates from the OncoMab pipeline. These antibodies have the ability to target and kill cancer cells and some have already proven effective in reducing tumour growth in animal models of cancer. The lead candidates will be jointly developed by Acceptys and OncoMab as therapies for colon, pancreatic and lung cancers.
Acceptys also has a new research agreement with the University of Wurzburg, Dr Peter Vollmers and Dr Hans Konrad Muller-Hermelink, whose work led to the discovery of OncoMab's lead therapeutic candidates. They plan to identify at least 40 more therapeutic candidates and associated production cell lines.